Lenvatinib (Lenvima)
Oral multikinase TKI for liver, thyroid, kidney, and endometrial cancers.
What is Lenvatinib?
What it targets
Multiple kinase pathways tumors rely on — VEGFR1-3, FGFR1-4, RET, KIT, and PDGFR-alpha — blocking both tumour growth signals and blood vessel formation.
Who it may help
Patients with hepatocellular carcinoma, radioactive iodine-refractory thyroid cancer, advanced kidney cancer, or selected advanced endometrial cancer.
Why testing matters
Liver and kidney function, blood pressure, and thyroid function must be checked before starting; no single biomarker test determines eligibility.
Which cancers can Lenvatinib treat?
Lenvatinib is approved for use in four cancer types across multiple treatment settings.
| Hepatocellular carcinoma (HCC) | First-line treatment for unresectable HCC in selected patients. Approved in 80+ countries. China approved lenvatinib plus pembrolizumab plus TACE for unresectable non-metastatic HCC in 2025 (LEAP-012 trial). |
| Differentiated thyroid cancer (DTC) | For locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer including papillary, follicular, and Hurthle cell types. |
| Renal cell carcinoma (RCC) | With pembrolizumab as first-line for advanced RCC; with everolimus for previously treated advanced RCC after prior anti-angiogenic therapy. |
| Endometrial carcinoma | With pembrolizumab for advanced pMMR (not MSI-H) endometrial carcinoma after prior systemic therapy when curative surgery or radiation is not possible. |
Who may be eligible for Lenvatinib?
Eligibility depends on cancer type, stage, biomarker results, organ function, blood pressure, and treatment history. Your oncologist will assess all these factors together.
- Confirmed HCC with unresectable disease and adequate liver function (Child-Pugh A preferred).
- Differentiated thyroid cancer that is progressive and no longer responds to radioactive iodine treatment.
- Advanced RCC eligible for first-line combination therapy or who have received prior anti-angiogenic therapy.
- Advanced endometrial carcinoma with pMMR or not MSI-H status confirmed by an approved diagnostic test.
- Blood pressure that is controlled or controllable with medicines before starting treatment.
- Adequate kidney function and urine protein levels within acceptable range at baseline.
- No recent major surgery, active bleeding, unhealed wounds, or significant gastrointestinal fistula.
- Performance status adequate for oral targeted therapy (typically ECOG 0 to 1).
How does Lenvatinib work?
- Blocking tumour blood supply (anti-angiogenesis)
- Blocking fibroblast growth factor signalling (FGFR)
- Blocking RET, KIT, and PDGFR-alpha
- Synergy with immunotherapy (pembrolizumab)
Tests needed before and during Lenvatinib treatment
Baseline and monitoring tests are required before starting lenvatinib and throughout treatment to ensure safety and assess response.
| Biopsy and histopathology | Confirms cancer type and grade before treatment initiation. |
| CT scan or MRI | Baseline tumour imaging for staging and response assessment. PET-CT where appropriate. |
| Liver function tests (LFTs) | Required before starting and monitored throughout. Child-Pugh score assessed for HCC. |
| Kidney function and urine protein | Serum creatinine, eGFR, and urine protein-creatinine ratio at baseline and during treatment. |
| CBC (complete blood count) | Baseline and periodic monitoring for cytopenias and treatment tolerability. |
| Blood pressure assessment | Must be controlled before starting lenvatinib. Regular monitoring required throughout treatment. |
| Thyroid function tests (TSH, T4) | Baseline and monitoring during treatment; lenvatinib commonly affects thyroid function. |
| MMR / MSI testing (endometrial cancer) | Required to confirm pMMR or not MSI-H status for lenvatinib plus pembrolizumab eligibility. |
| Hepatitis B and C serology (HCC) | Relevant in liver cancer patients to assess viral hepatitis status before treatment. |
| Electrolytes and cardiovascular review | Electrolyte panel and cardiovascular risk review, especially for patients with pre-existing heart disease. |
How is Lenvatinib given?
Lenvatinib is taken as oral capsules at home, usually once daily. The dose depends on cancer type, body weight in some settings, combination partner, and organ function.
| Dose — differentiated thyroid cancer | 24 mg orally once daily as a flat dose, regardless of body weight. |
| Dose — HCC (body weight below 60 kg) | 12 mg orally once daily. Consult your oncologist — dosing for HCC is weight-based and liver-function dependent. |
| Dose — first-line RCC with pembrolizumab | 20 mg orally once daily with pembrolizumab 200 mg IV every 3 weeks. |
| Dose — previously treated RCC with everolimus | 18 mg orally once daily with everolimus 5 mg once daily. |
| Dose — endometrial carcinoma with pembrolizumab | 20 mg orally once daily with pembrolizumab 200 mg IV every 3 weeks. |
| How to take | Take with or without food. Swallow capsules whole with water. Do not crush or open capsules. |
| Timing | Take at approximately the same time each day. Consistency helps maintain steady blood levels. |
| Missed dose | If the next dose is more than 12 hours away, take as soon as you remember. If less than 12 hours remain, skip and resume the next day. Never double up. |
| Dose modification | Dose interruption or reduction may be needed for hypertension, proteinuria, diarrhea, or liver changes. Your oncologist manages all adjustments. |
| Duration | Continued as long as the cancer is controlled and side effects are tolerable. Duration is individualised based on response and tolerability. |
Clinical evidence and potential benefits of Lenvatinib
Lenvatinib has demonstrated meaningful clinical activity across its approved indications in large phase III trials.
| HCC — REFLECT trial vs sorafenib | Lenvatinib demonstrated non-inferiority to sorafenib in overall survival and substantially higher objective response rates and longer progression-free survival in first-line unresectable HCC. |
| Differentiated thyroid cancer — SELECT trial | Lenvatinib substantially prolonged progression-free survival compared with placebo in radioactive iodine-refractory differentiated thyroid cancer, with a meaningful proportion of patients achieving tumour response. |
| First-line RCC — CLEAR trial with pembrolizumab | Lenvatinib plus pembrolizumab substantially improved progression-free and overall survival versus sunitinib, supporting its approval as a first-line standard of care combination in advanced RCC. |
| Endometrial carcinoma — KEYNOTE-775 with pembrolizumab | Lenvatinib plus pembrolizumab improved progression-free and overall survival versus chemotherapy in previously treated advanced endometrial carcinoma, particularly in pMMR patients. |
| HCC — LEAP-012 triple combination (China 2025) | Lenvatinib plus pembrolizumab plus TACE was approved in China in 2025 for unresectable non-metastatic HCC, combining systemic and locoregional approaches. |
| Oral convenience | As a home-based oral therapy for monotherapy indications, lenvatinib avoids repeated hospital infusions while requiring regular outpatient monitoring. |
Individual outcomes vary based on cancer type, stage, liver function, prior treatments, and overall health. These represent published clinical trial findings and are not guarantees of outcome.
Side effects of Lenvatinib
Lenvatinib causes targeted therapy-specific side effects that differ from chemotherapy. Most are manageable with monitoring and dose adjustment, but some require prompt medical attention.
| Hypertension | Very common. Blood pressure rises in a large proportion of patients. Regular monitoring is essential; antihypertensive medicines are often added or adjusted. |
| Fatigue and weakness | Common throughout treatment. Usually manageable with rest and activity pacing but may require dose reduction if severe. |
| Diarrhea | Common. Managed with dietary changes, oral rehydration, and anti-diarrheal medicines. Persistent or severe diarrhea requires medical review and may require dose hold. |
| Nausea and vomiting | Common. Antiemetic medicines can help. Taking lenvatinib with food may reduce nausea in some patients. |
| Reduced appetite and weight loss | Common. Nutritional support and dietitian input may be needed, especially with prolonged treatment. |
| Hand-foot skin reaction (HFSR) | Redness, pain, blistering or thickening of palms and soles. Preventive foot care and emollient creams can reduce severity. |
| Mouth sores (stomatitis) | Common. Gentle oral hygiene, alcohol-free mouthwash, and topical treatments help. Severe cases may require dose modification. |
| Hoarseness and voice change | Relatively common with lenvatinib. Usually mild but can be persistent. Inform your doctor if troublesome. |
| Proteinuria (protein in urine) | Requires monitoring. Dose reduction or hold may be needed if protein levels are high. |
| Hypothyroidism | Thyroid function monitoring required during treatment. Thyroid hormone replacement is straightforward if hypothyroidism develops. |
| Liver toxicity (hepatotoxicity) | Regular LFT monitoring required. Dose hold or reduction may be necessary for significant LFT elevation. |
| Kidney impairment | Renal function monitoring is essential. Dose adjustment may be needed based on creatinine changes. |
Contact your doctor immediately if you develop:
- Severe headache, blurred vision, or confusion — may indicate hypertensive crisis or RPLS.
- Chest pain, shortness of breath, or sudden leg swelling — possible cardiac or clotting emergency.
- Vomiting blood, black stools, or sudden severe abdominal pain — possible GI bleed or perforation.
- Sudden weakness, numbness, or difficulty speaking — possible stroke or arterial event.
- Severe or bloody diarrhea not improving within 24 hours despite home treatment.
- Yellowing of skin or eyes, dark urine, or severe upper-right abdominal pain — signs of liver problems.
- If on pembrolizumab: new rash, breathing difficulty, or severe diarrhea may indicate immune-related adverse effects.
Safety precautions and drug interactions
Tell your oncologist, cardiologist, and pharmacist about all medicines, supplements, and herbal products before starting lenvatinib.
- CYP3A4 inducers such as rifampicin, carbamazepine, or phenytoin may reduce lenvatinib blood levels.
- Strong CYP3A4 inhibitors including certain antifungals and HIV medicines may increase lenvatinib exposure.
- Stop lenvatinib before major surgery; wound healing can be impaired. Oncologist and surgeon must coordinate timing.
- Pregnancy: lenvatinib can harm an unborn baby. Effective contraception is required during and for a defined period after stopping treatment.
- Breastfeeding is not recommended during lenvatinib treatment or for a defined period after the last dose.
- Hepatitis B patients need viral load monitoring; reactivation can occur during lenvatinib treatment.
- Liver cirrhosis (Child-Pugh B or C): lenvatinib is not recommended — hepatotoxicity risk is substantially higher.
- History of arterial thromboembolism (heart attack, stroke): requires careful risk assessment before starting lenvatinib.
- If on anticoagulants: monitor closely. Lenvatinib affects bleeding risk and interactions need pharmacist-oncologist review.
- Inform your dentist you are on lenvatinib before any dental procedures. Wound healing may be slower.
Lenvatinib combination treatments
Lenvatinib may be used as monotherapy or in combination with immunotherapy or targeted agents, depending on cancer type, treatment line, and patient eligibility.
| Lenvatinib alone — HCC | First-line standard for unresectable HCC. Non-inferior to sorafenib in overall survival with higher response rates in the REFLECT trial. |
| Lenvatinib alone — thyroid cancer | Standard for progressive radioactive iodine-refractory differentiated thyroid cancer based on SELECT trial data. |
| Lenvatinib + pembrolizumab — first-line RCC | FDA and EMA approved. CLEAR trial showed substantial improvement over sunitinib in progression-free and overall survival. |
| Lenvatinib + everolimus — previously treated RCC | For advanced RCC after prior anti-angiogenic therapy. Combines two different pathway inhibitors in this second-line setting. |
| Lenvatinib + pembrolizumab — endometrial carcinoma | For pMMR or not MSI-H advanced endometrial carcinoma after prior platinum-based therapy per KEYNOTE-775 data. |
| Lenvatinib + pembrolizumab + TACE — HCC (China) | NMPA approved in China in 2025 (LEAP-012). Triple combination of systemic immunotherapy, TKI, and locoregional liver-directed therapy. |
| Investigational combinations | Lenvatinib is being studied with additional immunotherapy agents, locoregional therapies, and in earlier treatment settings. |
If Lenvatinib stops working
If lenvatinib loses effectiveness, the oncologist will reassess disease biology, organ function, and treatment options to guide next steps.
| Progression on lenvatinib — HCC | Second-line options include regorafenib, cabozantinib, or ramucirumab (for AFP-high patients), depending on performance status and liver function. |
| Progression on lenvatinib — thyroid cancer | Molecular testing may identify RET mutations (selpercatinib), NTRK fusions (larotrectinib), or BRAF V600E. Cabozantinib is an approved second-line option for thyroid cancer. |
| Progression on lenvatinib — RCC | Multiple approved second-line options exist including cabozantinib, axitinib, and nivolumab-based regimens depending on prior therapy. |
| Progression on lenvatinib — endometrial carcinoma | Additional biomarker testing including MSI, HER2, and NTRK may open targeted options. Carboplatin-paclitaxel or hormonal therapy may be considered. |
| Clinical trials at progression | Patients progressing on lenvatinib should ask whether a trial is available in India, China, Singapore, or internationally. Next-generation combinations are actively under investigation. |
Cost of Lenvatinib by country
Lenvatinib (Lenvima) remains a patented branded drug in most markets as of 2026. Cost varies substantially by country, insurance coverage, and access programme availability.
| India | Lenvima is available through licensed importers. Monthly cost can be significant without insurance. Ask your oncologist or navigator about current access routes and assistance options from Eisai. |
| USA | Covered by most insurance plans for approved indications. Eisai PAPLink patient assistance programme supports uninsured or underinsured patients. Out-of-pocket cost without insurance is very high. |
| UK / Europe | NHS in the UK covers Lenvima for approved indications. Most EU countries provide national reimbursement. Self-pay cost is high. |
| China | Lenvima is reimbursed through the NRDL for HCC, substantially reducing patient cost. The 2025 triple-combination approval may affect future reimbursement decisions. |
| Japan | National insurance covers approved indications. Patient co-pay is typically low under Japan's public health system. |
| Other countries | Access and cost vary widely in Southeast Asia, South Asia, and MENA. CancerFax can help patients explore legitimate access routes and assistance programmes. |
Availability of Lenvatinib globally
Lenvatinib monotherapy for HCC is approved in more than 80 countries. Combination approvals vary by country and indication. Access depends on registration, hospital formulary, and reimbursement policies.
India
Lenvima is available through licensed importers and specialty oncology pharmacies. Generics are not yet domestically approved. Access support via oncologist prescription and patient assistance programmes is the primary route.
China
NMPA approved for HCC and included in the NRDL, substantially reducing cost. 2025 LEAP-012 approval adds lenvatinib plus pembrolizumab plus TACE for unresectable non-metastatic HCC at major cancer centres.
USA
FDA approved for all four major indications. Available at major oncology centres and specialty pharmacies. Eisai PAPLink patient assistance programme available for eligible uninsured or underinsured patients.
United Kingdom
NICE approved and NHS funded for thyroid cancer, RCC, and endometrial cancer indications. Available at all major NHS cancer centres and oncology services.
Japan
Lenvima was first developed and approved in Japan. National health insurance covers approved indications with low patient co-pay. Available widely at cancer hospitals and oncology centres.
Europe (EU)
EMA approved for differentiated thyroid cancer, HCC, and endometrial carcinoma in combination with pembrolizumab. National reimbursement varies — most major EU health systems cover approved indications.
Lenvatinib in current clinical trials
Lenvatinib continues to be studied in clinical trials exploring new combinations, earlier treatment settings, and additional cancer types beyond current approvals.
| LEAP programme (lenvatinib + pembrolizumab) | The broad LEAP clinical programme continues to study this combination across multiple tumour types including hepatobiliary cancers, melanoma, and head and neck cancers. |
| Earlier-line HCC strategies | Trials evaluating lenvatinib combined with locoregional liver-directed therapies (TACE, ablation) and systemic immunotherapy in earlier-stage or potentially resectable HCC. |
| Thyroid cancer new combinations | Studies exploring lenvatinib with targeted agents or immunotherapy in RET-altered or aggressive thyroid cancers and underserved differentiated thyroid cancer subtypes. |
| Biomarker-selected endometrial cancer | Research to identify molecular subsets most likely to benefit from lenvatinib combinations, and to define effective therapy for MSI-H or POLE-mutated tumours outside the current approval. |
| Trial access in India and China | LEAP and investigator-initiated trials are available at leading cancer centres in India and China. CancerFax can help patients determine eligibility and access in their region. |
Your treatment journey with Lenvatinib
Diagnosis and staging
Biomarker and organ function testing
Oncology consultation and treatment planning
Starting lenvatinib
Early weeks — monitoring and adjustment
First response assessment scan
Long-term monitoring
If lenvatinib stops working
Questions to ask your oncologist about Lenvatinib
- Is lenvatinib appropriate for my cancer type and stage?
- Will I receive lenvatinib alone or combined with pembrolizumab or everolimus?
- What is the correct dose for my case and how might it change?
- Do I need MMR, MSI, NGS, or other biomarker testing before starting?
- How often will my blood pressure and blood tests be checked?
- What side effects should I call you about immediately?
- Should lenvatinib be stopped before surgery or dental procedures?
- What are my options if lenvatinib stops working?
- Is there a clinical trial I should consider?
How CancerFax supports Lenvatinib patients
CancerFax helps patients and families understand lenvatinib eligibility, navigate access options, and connect with experienced oncologists in India, China, and internationally.
| Medical report review | Upload your pathology, imaging, LFTs, kidney function, urine protein, and blood pressure reports. Our team reviews eligibility and explains what the results mean for lenvatinib candidacy. |
| Specialist oncologist connection | We connect patients with hepatologists, thyroid oncologists, and urologic oncologists experienced in HCC, thyroid, RCC, and endometrial cancer treatment in India, China, and other countries. |
| Second opinion coordination | If you are unsure whether lenvatinib or a combination regimen is right for your case, CancerFax arranges a second opinion with a relevant specialist. |
| Access support for India and China | We help patients understand how to access Lenvima through legal channels, assist with patient assistance programme enquiries, and coordinate treatment at major cancer centres. |
| China HCC and LEAP trial access | CancerFax has strong connections with Fudan Shanghai Cancer Center, GoBroad, and Sun Yat-sen Cancer Center for patients seeking TACE-plus-lenvatinib combinations or LEAP programme trials. |
| Treatment cost planning | We help families understand total treatment costs — drug, monitoring tests, imaging, hospital visits, and combination partner costs — so they can plan realistically before starting therapy. |
Frequently asked questions about Lenvatinib
Common questions from patients and caregivers about Lenvima
Lenvatinib (brand name Lenvima) is an oral targeted therapy for selected patients with liver cancer (hepatocellular carcinoma), radioactive iodine-refractory differentiated thyroid cancer, advanced kidney cancer (renal cell carcinoma), and selected advanced endometrial carcinoma. It blocks tumour growth and blood-vessel formation signals including VEGFR, FGFR, RET, KIT, and PDGFR. Not every patient with these cancers is eligible — your oncologist will assess your diagnosis, stage, liver function, blood pressure, and prior treatments before recommending it.
No. Lenvatinib is a targeted therapy, not chemotherapy. It is a multikinase tyrosine kinase inhibitor (TKI) that selectively blocks specific molecular pathways fuelling tumour growth and blood-vessel formation. Unlike chemotherapy, it does not broadly attack all rapidly dividing cells. Side effects differ — high blood pressure, hand-foot skin reaction, and proteinuria are more characteristic of lenvatinib than the nausea, hair loss, or bone marrow suppression typical of many chemotherapy drugs.
Unlike EGFR or BRAF-targeted drugs, bevacizumab does not require a specific tumor mutation test before treatment. It targets the angiogenesis pathway that most solid tumors depend on. However, your doctor will still need to screen you carefully for bleeding risk, blood pressure, kidney function, urine protein levels, and surgical history before starting treatment. In liver cancer, an endoscopy may also be required to check for varices.
Commonly reported side effects include high blood pressure, fatigue, diarrhea, reduced appetite and weight loss, nausea, hand-foot skin reaction, mouth sores, hoarseness, proteinuria, and low thyroid function. Most are manageable with dose adjustments and supportive medicines, but require regular monitoring. Serious side effects — severe hypertension, liver toxicity, kidney impairment, gastrointestinal perforation, and blood clots — can occur and require prompt medical attention.
Yes, in selected indications. Lenvatinib plus pembrolizumab is FDA and EMA approved for first-line advanced renal cell carcinoma and for selected advanced endometrial carcinoma after prior systemic therapy. In 2025, China approved the combination with TACE for unresectable, non-metastatic hepatocellular carcinoma based on the Phase III LEAP-012 trial. This combination requires careful monitoring for both TKI-related and immune-related adverse effects. Your oncologist will determine whether it is appropriate for your cancer type and stage.
As of 2026, lenvatinib remains under patent protection in most major markets, and generic versions are not yet widely available. The branded product Lenvima is manufactured by Eisai. Availability, cost, and access assistance vary significantly by country. Patients in India, China, and other countries should ask their oncologist or navigator about current local access routes. CancerFax can help explore access options in India, China, and other oncology treatment centres.
If lenvatinib stops controlling your cancer, your oncologist will review imaging results, reassess liver and kidney function, and consider next-line options. For HCC, options include regorafenib, cabozantinib, or ramucirumab depending on prior therapy. For thyroid cancer, molecular testing may identify RET, NTRK, or BRAF-targeted options. For RCC and endometrial cancer, multiple approved agents exist. Clinical trials should always be explored at progression, especially when standard options are limited.
Lenvatinib frequently causes or worsens hypertension and requires careful blood pressure monitoring before and throughout treatment. Patients with pre-existing high blood pressure can be considered for lenvatinib, but blood pressure must be well controlled before starting. Your oncologist and cardiologist may need to adjust antihypertensive medications. Lenvatinib should be withheld if blood pressure is not adequately controlled and may need permanent discontinuation in severe cases. Never start or adjust lenvatinib without medical supervision.